Rezulin is a drug manufactured by Warner-Lambert/Parke-Davis Company
used to treat Type 2 Diabetes. Rezulin (troglitazone) was banned in England in
December 1997. On March 22, 2000, the manufacturer announced that it
was discontinuing the sale of Rezulin
in the United States after the
Federal Drug Administration determined that it was too dangerous for
use. Some patients had experienced severe liver problems including liver failure and even death.
Before the ban, sales of Rezulin produced $1.8 billion in revenues.
Stats of known effects of Rezulin:
• 7 liver transplant survivors
• 10 recoveries without a liver transplant
• 10 people continuing to suffer from liver failure
• 63 deaths